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Benedict J. Kolber,1Michael C. Montana,1,2 Yarimar Carrasquillo,1 Jian Xu,3 Stephen F. Heinemann,3 Louis J. Muglia,4
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The central nucleus of the amygdala (CeA) has been identified as a site of nociceptive processing important for sensitization induced by
peripheral injury.However, the cellular signaling components underlying this function remainunknown.Here,we identifymetabotropic
glutamate receptor 5 (mGluR5) as an integral component of nociceptive processing in the CeA. Pharmacological activation of mGluRs
with (R,S)-3,5-dihydroxyphenylglycine (DHPG) in the CeA of mice is sufficient to induce peripheral hypersensitivity in the absence of
injury. DHPG-induced peripheral hypersensitivity is reduced via pharmacological blockade ofmGluR5 or genetic disruption ofmGluR5.
Furthermore, pharmacological blockadeor conditionaldeletionofmGluR5 in theCeAabrogates inflammation-inducedhypersensitivity,
demonstrating the necessity of mGluR5 in CeA-mediated pain modulation. Moreover, we demonstrate that phosphorylation of
extracellular-signal regulated kinase 1/2 (ERK1/2) is downstreamofmGluR5 activation in theCeAand is necessary for the full expression
of peripheral inflammation-induced behavioral sensitization. Finally, we present evidence of right hemispheric lateralization ofmGluR5
modulation of amygdalar nociceptive processing. We demonstrate that unilateral pharmacological activation of mGluR5 in the CeA
produces distinct behavioral responses depending on whether the right or left amygdala is injected. We also demonstrate significantly
higher levels of mGluR5 expression in the right amygdala compared with the left under baseline conditions, suggesting a potential
mechanism for right hemispheric lateralizationof amygdala function inpainprocessing. Together, these results establish an integral role
for mGluR5 and ERK1/2 in nociceptive processing in the CeA.
Introduction
The amygdala is selectively activated in both humans and rodents
during pain (Schneider et al., 2001; Lu et al., 2004; Han and
Neugebauer, 2005; Carrasquillo and Gereau, 2007; Ikeda et al.,
2007). Within the amygdala, the central nucleus (CeA) is well
positioned to regulate nociceptive processing via input through
the spino-parabrachio-amygdaloid pathway or through the ba-
solateral nucleus of the amygdala (BLA) (Neugebauer et al.,
2004). Within the CeA, the laterocapsular division (CeLC) has
been identified as a putative pain regulatory center, in part be-
cause of the sensitivity of neurons within this region to noxious
stimuli.
After induction of painful arthritis in rats, neurons in the
CeLC exhibit increased baseline firing and an enhanced response
to noxious stimuli (Li and Neugebauer, 2004). In addition, acti-
vation of CeLC group I metabotropic glutamate receptors
(mGluR1 andmGluR5) with the selective group ImGluR agonist
(R,S)-3,5-dihydroxyphenylglycine (DHPG) potentiates the re-
sponse of CeLC neurons to painful stimuli (Neugebauer et al.,
2003; Li and Neugebauer, 2004). These data suggest that group
I mGluRs in the CeA could be critical to nociceptive process-
ing in this nucleus. However, the specific contributions of
mGluR1 and mGluR5, as well as those of downstream regula-
tors, are unknown.
mGluR1 andmGluR5 are expressed throughout the pain neu-
roaxis (Ryo et al., 1993; Romano et al., 1995) and have been
identified as important molecular components of nociception
(Bhave et al., 2001; Karim et al., 2001b; Varney andGereau, 2002;
Li and Neugebauer, 2004; Han and Neugebauer, 2005; Hu et al.,
2007; Ansah et al., 2009). Activation of mGluR5 can lead to
ERK1/2 (extracellular-signal regulated kinase 1/2) phosphoryla-
tion (activation) via the intracellular MAPK (mitogen-activated
protein kinase) cascade (Karim et al., 2001a). This signaling cas-
cade has been shown to be critical for sensitization of spinal dor-
sal horn neurons (Hu and Gereau, 2003; Hu et al., 2003), a
mechanism underlying enhancement of pain-like behavior after
peripheral inflammation (Karim et al., 2001a; Adwanikar et al.,
2004). In the context of peripheral inflammation, activation of
ERK in theCeA ofmice occurs in a lateralizedmanner, withmore
ERK activation occurring in the right amygdala compared with the
left (Carrasquillo and Gereau, 2008), and is necessary for
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inflammation-induced mechanical hypersensitivity (Carrasquillo
and Gereau, 2007). Furthermore, activation of ERK in the amyg-
dala induces pain-like behavior in the absence of any peripheral
injury, a phenomenon that may have important implications for
pain syndromes that are not associated with an identified tissue
injury. However, at this point the role of mGluR5 in this process
is unknown.
In the present study, we sought to test the hypothesis that
mGluR5 activation and downstream ERK1/2 activation in the
CeA are necessary and sufficient for nociceptive behavioral sen-
sitization. Utilizing both pharmacological and genetic tech-
niques, we demonstrate that right amygdala mGluR5 activation
induces bilateral tactile hypersensitivity and that mGluR5 activa-
tion, but not endocrine feedback, is required for the mechanical
hypersensitivity induced by peripheral inflammation. We dem-
onstrate that mGluR5-mediated hypersensitivity is functionally
coupled to and dependent on ERK1/2 activation. Finally, we find
that mGluR5 expression is greater in the right amygdala relative
to the left amygdala.
Materials andMethods
Animals
All mouse protocols were in accordance with National Institutes of
Health guidelines and were approved by the Animal Care and Use Com-
mittees of Washington University School of Medicine (St. Louis, MO).
Male mice (all C57BL/6 background) were housed on a 12/12 h light/
dark cycle [lights on at zeitgeber time (ZT) 0] with ad libitum access to
rodent chow and water. Unless otherwise stated, wild-type (WT)
C57BL/6J (The Jackson Laboratory) male mice age 6–8 weeks were used
for pharmacological studies.
mGluR5KO. Conventional mGluR5 knock-out (mGluR5KO) male
mice have been described previously (Jia et al., 1998) and were obtained
from The Jackson Laboratory. For pharmacological testing with
mGluR5KO mice, cannula verification was done as described below.
GRCeAKO. Mice homozygous for the GRloxP allele were stereotaxically
injected into bilateral CeAs with either lentiviral (LV) vector LV-Ef1-
Cre (GRCeAKO) or LV-Ef1-GFP (control mice; where GFP is green
fluorescent protein) as described previously (Kolber et al., 2008). Briefly,
mice were anesthetized andmounted in a stereotaxic frame. A small hole
was drilled over the right and left CeAs (coordinates: 1.25mmanterior to
bregma; 2.7 mm lateral to midline; 4.7 mm ventral to skull). A 32-
gauge needle was lowered into the hole and left in place for 1 min before
injection of virus. Infectious viral particles (4 105) were injected over 5
min and the needle was left in place for 5min after injection. All testing in
these mice occurred 2 wk after recovery from surgery. After testing,
brains were sectioned to determine needle targeting and the percentage
of NeuN-positive glucocorticoid receptor (GR)-expressing cells as a
measure of GR disruption in the CeA and nearby BLA. It was previously
determined that GRCeAKO mice have 34.8 1.97% NeuN-positive GR-
expressing cells compared with 95.0  0.48% NeuN-positive GR-
expressing cells in the CeA of control LV-GFP-injected mice (Kolber et
al., 2008). No significant differences were observed in the BLA in either
LV-Cre or LV-GFP-injected mice.
mGluR5CeAKO.Mice homozygous for themGluR5loxP allele (Xu et al.,
2009) orWT littermates were used. All animals were injected in the right
amygdala with recombinant lentiviral vector LV-Ef1-Cre (LV-Cre)
similarly as described previously (Kolber et al., 2008). Briefly, mice were
anesthetized with a combination ketamine/xylazine anesthetic and
mounted in a stereotaxic frame. A small hole was drilled over the right
CeA (coordinates: 1.25 mm anterior to bregma; 2.7 mm lateral to mid-
line; 4.7 mm ventral to skull). A 32-gauge needle was lowered into the
hole and left in place for 1 min before injection of virus. Infectious viral
particles (4  105) were injected over 5 min and the needle was left in
place for 5 min after injection. All testing in these mice occurred 2 wk
after recovery from surgery. After testing, brains were sectioned to deter-
mine needle targeting and 1 mm diameter  1 mm high punches were
made of the amygdala in two adjacent sections to determine the amount
of mGluR5 disrupted in floxed mice compared with WT mice injected
with LV-Cre. See below for processing of tissue punches.
Surgical procedure for cannula implantation
Mice were deeply anesthetized with a combination ketamine/xylazine
anesthetic and mounted in a stereotaxic frame. Stainless steel guide can-
nulas (8mm) were implanted at the CeA (coordinates: 1.25mm anterior
to bregma; 2.70 mm lateral to midline; 4.2 mm ventral to skull). The
guide cannula was affixed to the skull with two bone screws (Stoelting)
and dental cement. An 8 mm stylet was inserted in the guide cannula to
prevent clogging.Mice recovered for 6 d before further testing. At the end
of experiments, brains were sectioned to verify cannula position and
injection site.
Intra-amygdala drug infusions
Injection procedures. Microinjections were performed as described previ-
ously (Carrasquillo and Gereau, 2007). Briefly, injections were per-
formed using a 32-gauge injection cannula that extended 0.5mmbeyond
the tip of the guide cannula. The injection cannula was attached to flex-
ible plastic tubing and a microliter syringe (Hamilton) was used to de-
liver drugs. A total volume of 0.3 l was infused over a period of 3 min
and the injection cannula was kept in place for an additional 1 min to
allow for drug infusion.
Drugs injected. DHPG (Tocris Bioscience) is a potent agonist that ac-
tivates bothmGluR5 andmGluR1. On the day of the experiment, DHPG
was dissolved in artificial CSF (aCSF) containing the following (in mM):
25 NaHCO3, 122 NaCl, 1.3 CaCl2, 1.2 MgSO4, 3 KCl, and 0.4 KH2PO4,
pH 7.35, to a final stock solution of 5 mM. Stock solution was diluted in
aCSF or aCSF/DMSO to the final concentrations stated in the text.
2-Methyl-6-(phenylethynyl)pyridine hydrochloride (MPEP; Tocris Bio-
science) is a selective noncompetitive antagonist of mGluR5. On the day
of the experiment, MPEP was dissolved in aCSF to a final stock solution
of 5mM. Stock solutionwas diluted in aCSF to final concentrations stated
in the text. 1,4-Diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)
butadiene (U0126; Tocris Bioscience) was selected to inhibit ERK
activation. Experiments with U0126 were compared with the-negative
structural control analog 1,4-diamino-2,3-dicyano-1,4-bis(methylthio)
butadiene (U0124). U0126 and U0124 (Tocris Bioscience) were dis-
solved as described previously (Carrasquillo and Gereau, 2007). U0126
and U0124 were dissolved first in 100% DMSO to a 2 stock solution.
Final dilutionsweremade to be 50%DMSO/50%aCSF.Dosing ofU0126
was determined fromour previousworkwith this drug (Carrasquillo and
Gereau, 2007, 2008). For experiments using combinations of drugs, in-
dividual drugs were dissolved at 2 the stated final concentration and
then combined 1:1 with other drug. Unless otherwise stated, aCSF was
used as a vehicle control.
Behavioral testing
All behavioral testing was performed by an experimenter blinded to
pharmacological treatment and genotype and was done between ZT1
and ZT8.Mice were habituated (for2 h) and tested in 25 25 35 cm
ventilated Plexiglas enclosures with background white noise used to
mask randomnoise.Mechanical sensitivity wasmeasured using von Frey
filaments (North Coast Medical) as described previously (Fu et al., 2001;
Yang and Gereau, 2003). Each von Frey filament, starting with the small-
est, was applied to the mouse hindpaw until bent at 30° for 2 s. The
smallest filament that evoked a paw withdrawal response in at least three
of the five trials was taken as themechanical threshold for that trial. Three
to five baseline measurements were taken from each hindpaw on the day
before all drug or formalin experiments. The average withdrawal force
was calculated individually for each paw as the baseline. Mechanical
hypersensitivity was calculated by comparing withdrawal thresholds af-
ter drug/formalin to baseline withdrawal value. For DHPG, DHPG plus
MPEP, and DHPG plus U0126 experiments, intra-amygdala drug infu-
sions were performed 30 min before mechanical testing. In tests using
formalin-induced mechanical hypersensitivity, 10 l of 2% formalin
(Sigma) solution was injected subcutaneously in the plantar surface of
the right hindpaw. The right hindpawwas chosen for formalin treatment
because previous work from our laboratory (Carrasquillo and Gereau,
2007, 2008) and others (Ji and Neugebauer, 2009) has shown that
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inflammation-induced right CeA activation occurs independently of the
side of peripheral inflammation (i.e., right or left side of body). For
nonpharmacological experiments with mGluR5KO, mGluR5CeAKO, and
GRCeAKO mice, mechanical sensitivity was measured 3 h following in-
traplantar formalin injection. To determine the effects of MPEP on
formalin-induced mechanical hypersensitivity, intra-amygdala drug in-
fusionwas performed 2h after formalin injection andmechanical thresh-
olds were measured 1 h after intra amygdala drug infusion, which
corresponds to 3 h after formalin injection in the paw.
The formalin test tomeasure spontaneous behaviors following forma-
lin injection was performed as described previously (Bhave et al., 2001).
mGluR5CeAKO and control mice were videotaped following intradermal
formalin injection and analyzed offline for nociceptive behavior (defined
as licking, lifting, and flinching of the injected paw) in 5 min bins. The
first phase of spontaneous behavior was defined as 0–10 min after for-
malin, and then the second phase of testing was defined as 10–35 min
after formalin injection.
Western blotting
All plots of Western quantification are normalized to the control (e.g.,
vehicle) left amygdala level of protein and are expressed as “fold control.”
DHPG and DHPG/U0126 ERK1/2 activation. Following intra-
amygdala infusion of 0.1 nmol of DHPG alone (compared with vehicle)
or DHPG plus U0126 (compared with DHPG plus U0124), brains were
removed and sectioned into 1-mm-thick coronal sections using an
acrylic brain matrix (Stoelting). From the two appropriate sections,
amygdala punches (two per side per animal) were obtained using a
custom-made 1mmpunch tool. Samples were frozen on dry ice and then
homogenized in ice-cold homogenization buffer (20 mM Tris-HCl, pH
7.4, 1mMEDTA, 1mM sodiumpyrophosphate,
25 g/ml aprotinin, 25 g/ml leupeptin, 1
g/ml microcystein, 1 mM sodium orthovana-
date, and 100 M phenylmethylsulfonyl fluo-
ride; Sigma) using a Dounce homogenizer.
Protein concentrations were determined using
the BCA protein assay kit (Pierce Biotechnol-
ogy). The levels of ERK activation in the amyg-
dala were measured by Western blotting using
antibodies specific for phosphorylated ERK
(pERK) and total ERK. Total protein (5g) for
amygdala homogenates was run using 4–12%
SDS-PAGE (Invitrogen) and transferred to ni-
trocellulose membranes (Whatman). Blots were
blocked inOdysseyblockingbuffer (Licor) for1h
and then coincubated in mouse anti-p44/42
ERK (1:1000, Cell Signaling Technology, Bev-
erly,MA) and rabbit antiphospho-p44/42 ERK
(1:1000; Cell Signaling Technology) primary
antibodies in Odyssey buffer with 0.1% Tween
20 (Sigma) for 1 h at room temperature (RT).
After washing in TBS with 0.1% Tween 20,
blots were incubated in goat anti-rabbit IR800
(1:20,000; Rockland) and goat anti-mouse Al-
exa 680 (1:20,000 Invitrogen) for 1 h at RT.
Blots were washed and scanned using anOdys-
sey scanner (Licor). Densitometry of bands
corresponding to ERK1 (p44) and ERK2 (p42)
was performed using Odyssey v3.0 software
(Licor).
Effect of MPEP on formalin-induced ERK1/2
activation. To determine the effects of MPEP
on formalin-induced ERK1/2 activation, intra-
right amygdala drug infusion was performed
2 h after formalin injection and brains were
removed 60 min after drug infusion, which
corresponds to 3 h after formalin injection in
the paw. Brains were sectioned into 1-mm-
thick coronal sections using an acrylic brain
matrix (Stoelting) From the two appropriate
sections, amygdala punches (two per side per
animal) were obtained using a custom-made 1mmpunch tool. Activated
ERK1/2 was analyzed as described above by Western blot.
Protein expression in mGluR5KO and mGluR5CeAKO mice. Brains were
removed from mGluR5KO mice (compared with WT mice) or
mGluR5CeAKO mice (compared with LV-Cre-injected WT mice) and
sectioned into 1 mm-thick coronal sections. From the two appropriate
sections, amygdala punches (two per side per animal) were processed as
described above with ice-cold homogenization buffer (20 mM Tris-HCl,
pH 7.4, 1 mM EDTA, 1 mM sodium pyrophosphate, 25 g/ml aprotinin,
25 g/ml leupeptin, and 100 M phenylmethylsulfonyl fluoride). The
levels of mGluR5 or GR in the left or right amygdala were measured by
Western blotting using antibodies specific for mGluR5 or GR and the
loading control protein -tubulin. Total protein (3–5 g) for amygdala
homogenates was run using 4–12% SDS-PAGE and transferred to nitro-
cellulose membranes. For mGluR5Western blotting, blots were blocked
in Odyssey blocking buffer for 1 h and then coincubated in mouse anti-
-tubulin (1:10,000; Sigma) and rabbit anti-mGluR5 (1:1000;Millipore)
primary antibodies in Odyssey buffer with 0.1% Tween 20 for 1 h at RT.
For GRWestern blotting, blots were blocked in Odyssey blocking buffer
for 1 h and then coincubated in anti--tubulin and rabbit anti-GR (1:
1000; Santa Cruz Biotechnology) primary antibodies in Odyssey buffer
with 0.1% Tween 20 overnight at 4°C. After washing in TBS with 0.1%
Tween 20, blots were incubated in goat anti-mouse IR800 (1:20,000) and
goat anti-rabbit Alexa 680 (1:20,000) for 1 h at RT. Blotswerewashed and
scanned using an Odyssey scanner. Densitometry of bands correspond-
ing to mGluR5/GR and -tubulin was performed using Odyssey soft-
ware. Each mGluR5 or GR value was divided by the pixel value for that
A
B C
Figure 1. mGluR5 and phosphorylated ERK are expressed in the CeLC. A, Immunoreactivity showing mGluR5 expression (in
white) in WT mice (mGluR5 control mice; left) or conventional mGluR5 KO mice (right). No positive signal was seen in mGluR5 KO
sections. B, C, Magnified images demonstrate mGluR5 expression in the left (B; in white) and right CeLCs (C, left in white). C,
Additional panels for the right CeLC demonstrate thatmGluR5 (left panel, in white; right panel, in green) and phosphorylated ERK
(middle panel, in white; right panel, in magenta) are expressed in the CeLC of WT mice. Scale bars, 200m.
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sample’s -tubulin value and then normalized
to the left amygdala control.
Immunohistochemistry
DHPG-induced ERK activation. Thirtyminutes
after intra-amygdala infusion of 0.1 nmol of
DHPG (compared with vehicle), mice were
deeply anesthetized with 2.5% Avertin anes-
thesia and then perfused transcardially with
PBS (37°C), followed by 100 ml of ice-cold 4%
paraformaldehyde (PFA) solution in PBS. The
brain was dissected and postfixed in PFA over-
night at 4°C. After cryoprotection in 30% su-
crose, coronal sections (30 m) were obtained
on a cryostat and stored in PBS at 4°C until
immunostaining. Sections were rinsed in PBS,
incubated in 10% MeOH/0.3% H2O2 in PBS
for 30 min at RT, and blocked in 1% normal
goat serum (NGS) (Vector Laboratories) with
0.02% Triton X-100 for 1 h at RT. Sections
were incubated overnight at 4°C in rabbit anti-
phospho-p44/42 ERK antibody (1:1000; Cell
Signaling Technology) in blocking solution.
Sections were rinsed in PBS with 0.2% Triton
X-100 and incubated in goat anti-rabbit bio-
tinylated secondary antibody (1:200; Vector
Laboratories) in blocking solution for 120 min
at RT. Sections were rinsed in PBS with 0.2%
Triton X-100 and incubated in an avidin-
biotin complex (Vector Laboratories) for 60
min at RT. Sections were rinsed in PBS and
incubated in a Cy-3-conjugated tyramide signal
amplification reagent (PerkinElmer). Immu-
nohistochemical sections were wet mounted
and visualized using a Nikon Eclipse 80i fluorescent microscope. Note
that we typically see some amount of pERK immunofluoresence in naive
animals (Carrasquillo and Gereau, 2007).
mGluR5 and ERK inWT and mGluR5KO mice. Mice were deeply anes-
thetized andprocessed as above. Sectionswere first stained for phosphor-
ylated ERK as described above. Following ERK staining, sections were
then blocked in 3% NGS with 0.3% Triton X-100 for 1 h at RT. Sections
were incubated overnight at 4°C in anti-mGluR5 antibody (1:1500) in
blocking solution. Sections were rinsed in PBS with 0.2% Triton X-100
and incubated in goat anti-rabbit Alexa 488-conjugated secondary anti-
body (1:200, Invitrogen) in blocking solution for 60 min at RT. Immu-
nohistochemical sections were wet mounted and visualized using a
Nikon Eclipse 80i fluorescent microscope.
Data analysis
Results are expressed as means  SEM. Unpaired Student’s t tests were
used to compare pairs of means. To compare lateralization of protein,
paired Student’s t tests were used to compare two means from the same
group of mice (e.g., right versus left amygdala protein expression in
control mice). In cases of two independent variables [e.g., genotype and
treatment (preformalin and postformalin)], two-way ANOVA with re-
peated measures was used followed by Bonferroni post hoc tests when
significant main effects were found. A value of p 0.05 was considered
statistically significant for all statistical comparisons. All statistical com-
parisons were done with Prism 5 software (GraphPad).
Results
mGluR5 and activated ERK1/2 are expressed in the CeLC
We evaluated mGluR5 in the brains of WT and conventional
mGluR5 knock-out mice under naive conditions (Jia et al., 1998)
(Fig. 1A). mGluR5 expression in WT mice is highest in the hip-
pocampus, striatum, and a small section of the amygdala, but is
diffusely expressed throughout the parenchyma (Fig. 1A, left).
No positive immunohistochemical signal was detected in the
brains of mGluR5KOmice (Fig. 1A, right). InWTmice, mGluR5
is expressed in the CeLC, the putative nociceptive amygdala (Fig.
1B,C), with activated ERK1/2 (Fig. 1C). After identifying the
presence of mGluR5 in the CeLC, we tested the hypothesis that
mGluR5 activation in the amygdala is sufficient to induce me-
chanical hypersensitivity.
Intra-amygdala mGluR5 activation induces
mechanical hypersensitivity
Weused the von Frey test to determinewhether activation of CeA
group I mGluRs was sufficient to induce peripheral mechanical
hypersensitivity. The von Frey test is an established method for
determining mechanical sensitivity in mice (Fu et al., 2001).
Baseline withdrawal sensitivitymeasurements were performed in
WT mice, and 1 day later either DHPG (0.1 or 0.01 nmol) or
vehicle was infused into the right amygdala via a preimplanted
cannula (0.3 l over a 3 min period). Withdrawal to mechanical
stimulation was assessed 30min postinfusion. Infusion of DHPG
into the CeA significantly decreased mechanical withdrawal
thresholds in both hindpaws (Fig. 2A,B) compared with baseline
values and postvehicle thresholds.
Previous work has found that intracellular signaling cascades
critical to the modulation of mechanical hypersensitivity are
functionally lateralized to the right amygdala (Carrasquillo and
Gereau, 2007, 2008). To test whether this was also true for group
I mGluRs, we next examined the effects of left amygdala DHPG
infusion (0.1 nmol) on mechanical withdrawal thresholds.
Whereas right amygdala infusion ofDHPG induced bilateral hyper-
sensitivity, we found that left amygdala infusion induced hypersen-
sitivity in only the contralateral (right) hindpaw (Fig. 2C,D).
Subsequently, our studies focused on manipulations of the
right amygdala because previous work from our laboratories
(Carrasquillo and Gereau, 2007, 2008) and others (Ji and Neuge-
bauer, 2009) has shown that pain-related right CeA activation
Figure 2. Activation of amygdala mGluR5 induces mechanical hypersensitivity. A, B, DHPG, a selective group I mGluR agonist,
injected into the right amygdala (0.01 nmol, n 8; 0.1 nmol, n 8) causes significant mechanical hypersensitivity 30 min after
injection in both the left (A) and right (B) paws compared with vehicle-treated mice (n 8). C, D, DHPG injected into the left
amygdala (n 11) causes mechanical hypersensitivity in the right (D) but not in the left (C) paw compared with vehicle-treated
mice (n 10). Gray areas in brain illustrations are representative of WTmGluR5 expression. Data are expressed as mean SEM.
Repeated-measures ANOVA with Bonferroni post-test: **p  0.01, ***p  0.001, compared with vehicle-treated group at
specified time point; ##p 0.01, ###p 0.001, compared with baseline for specified group.
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occurs independently of the side of injury. To determine whether
the effects of right amygdala DHPG were due to specific activa-
tion of mGluR5, the noncompetitive mGluR5 antagonist MPEP
(0.001 nmol or 0.01 nmol) was coinfused with DHPG (0.1 nmol)
into the right amygdala of WT mice before testing. Mice coin-
fused with 0.01 nmol of MPEP and DHPG exhibited no changes
from baseline and significantly higher mechanical withdrawal
thresholds in both hindpaws than did mice coinfused with vehi-
cle and DHPG (Fig. 3A,B). The effects of MPEP were dose de-
pendent, as 0.001 MPEP coinfused with DHPG failed to inhibit
DHPG-induced hypersensitivity. In a separate experiment,
MPEP (0.01 nmol) alone did not significantly affect withdrawal
thresholds compared with those of vehicle-treatedmice (left paw
withdrawal threshold: vehicle n 6 0.43 0.07 g vs 0.01 nmol of
MPEP n  5 0.35  0.05 g; Student’s t test, p  0.41; right paw
withdrawal threshold: vehicle n 6 0.39 0.06 g vs 0.01 nmol of
MPEP n  5 0.39  0.07 g; Student’s t test, p  0.99). This
suggests that the effects of MPEP on DHPG-induced hypersensi-
tivity are not attributable to MPEP-induced alterations in me-
chanical sensitivity in the absence ofDHPG. Together, all of these
results demonstrate the necessity of amygdala mGluR5 in
DHPG-induced mechanical hypersensitivity.
In addition to pharmacological testing, we used mGluR5KO
mice to test for the necessity of mGluR5 in DHPG-induced me-
chanical hypersensitivity. Baseline withdrawal thresholds were
higher in mGluR5KO mice compared with those of WT litter-
mates (Fig. 3C,D). Following baseline testing, DHPG (0.1 nmol)
was infused into the right amygdalas of all mice. Whereas infu-
sion of DHPG induced robust bilateral hypersensitivity in WT
mice, we found that infusion of DHPG into mGluR5KO mice
failed to induce any significant mechanical hypersensitivity in
either paw (Fig. 3C,D). Overall, these data demonstrate the ne-
cessity of mGluR5 in DHPG-inducedme-
chanical hypersensitivity.
mGluR5 activation in the right
amygdala results in ERK1/2 activation
Thus far, we have demonstrated that
mGluR5 activation in the amygdala is suf-
ficient to induce mechanical hypersensi-
tivity in uninjured mice. To evaluate the
downstream signaling components of
mGluR5 activation in the amygdala, we
tested whether group I mGluR activation
would induce ERK1/2 activation. Repre-
sentative sections show activated ERK1/2
in the amygdala of mice infused with
DHPG (0.1 nmol) or vehicle into the right
amygdala (Fig. 4A). In a separate cohort of
mice, animals were injected with either
DHPG (0.1 nmol) or vehicle alone and
evaluated by Western blotting for amyg-
dalar ERK1 or ERK2 activation (Fig. 4B).
Quantification revealed that right amyg-
dala DHPG infusion induced a signifi-
cant increase in ERK1 (pERK1/totalERK1
expressed as fold control left amygdala)
(Fig. 4C) and ERK2 activation (pERK2/
totalERK2 expressed as fold control left
amygdala) (Fig. 4D) in the right amygdala
compared with samples taken from the
left amygdala of DHPG-injectedmice and
samples from vehicle-injected animals.
Given that ERK1/2 is activated by DHPG, we next asked
whether ERK activationmight be necessary for the observed right
amygdala DHPG-induced mechanical hypersensitivity. DHPG
(0.1 nmol in aCSF) was coinfused into the right amygdala of WT
micewith either aMEK1/2 inhibitor (U0126; 1.5 nmol inDMSO)
or an inactive control analog (U0124; 1.5 nmol inDMSO) 30min
before von Frey behavioral testing. DHPG infusion resulted in
significantly decreased paw withdrawal thresholds, which were
partially reversed by coinfusion with U0126 but not the inactive
analog U0124 (Fig. 4E,F). At this dose of U0126, we have previ-
ously shown no differences in mechanical sensitivity between
U0126- and vehicle-treated mice (Carrasquillo and Gereau,
2007), suggesting that the observed effects of U0126 on DHPG-
induced mechanical hypersensitivity are not caused by U0126-
mediated alterations in baseline sensitivity in the absence of
DHPG.
Following behavioral testing, we evaluated whether MEK1/2
inhibition with U0126 would block DHPG-induced ERK1/2 ac-
tivation. ERK1 and ERK2 activation after DHPG coinfusion with
either U0124 or U0126 is shown in a representative Western blot
(Fig. 4G). Quantification revealed that DHPG-induced ERK1/2 ac-
tivation in the right amygdala was significantly decreasedwith coin-
fusion of U0126 compared with coinfusion of U0124 (Fig. 4H).
Pharmacological blockade of mGluR5 inhibits formalin-
induced behavioral hypersensitivity and ERK1/2 activation
We have demonstrated that activation of mGluR5 in the amyg-
dala is sufficient to induce peripheralmechanical hypersensitivity
in the absence of any injury or painful stimulus. We next sought
to test the hypothesis that activation of mGluR5 in the right





Figure 3. mGluR5 is required for intra-amygdala DHPG-induced mechanical hypersensitivity. A, B, MPEP (an mGluR5 antago-
nist) (0.001 nmol, n 6; 0.01 nmol, n 6), but not vehicle (n 7), coinfused with DHPG (0.1 nmol) into the right amygdala
blocks mechanical hypersensitivity induced by DHPG in the left (A) and right (B) paws. C, D, DHPG injected in the right amygdala
induces mechanical hypersensitivity in WT mice (n 6) but not mGluR5 KO mice (n 5). Baseline withdrawal thresholds in
mGluR5 KO mice are higher than those of control mice. Gray area in brain illustration is representative of WT mGluR5 expression;
white area in brain illustration is representative of where mGluR5 is deleted. Data are expressed as mean SEM. Repeated-
measures ANOVA with Bonferroni post-test: *p 0.05, **p 0.01, ***p 0.001, compared with vehicle plus DHPG-treated
group (A, B) or mGluR5 WT mice (C, D) at specified time point; ##p 0.01, ###p 0.001, compared with baseline for specified
group.
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havior following formalin-induced pe-
ripheral inflammation (Fu et al., 2001;
Carrasquillo and Gereau, 2007).
To test whether blocking mGluR5 ac-
tivation in the right amygdala has an effect
on this nociceptive response, WT mice
were given right paw intraplantar injec-
tions of formalin (2% in saline) and 2 h
later were treated with either MPEP (0.01
nmol) or vehicle via right intra-amygdala
infusion. In all animals tested, withdrawal
thresholds to mechanical stimuli in both
paws were significantly reduced 1 h after
formalin injection. At 3 h, mechanical
withdrawal thresholds after MPEP infu-
sion were significantly higher in both
paws compared with withdrawal thresh-
olds in vehicle-infused mice (Fig. 5A,B).
Furthermore, MPEP infusion significantly
increased withdrawal thresholds in both
paws comparedwith 1 h postformalin val-
ues and returned withdrawal thresholds
in the noninjected (left) paw to a level that
was not significantly different from the
preformalin baseline (Fig. 5A). These re-
sults suggest that mGluR5 in the CeA is
necessary for the full behavioral response
to intraplantar formalin.
Previous work has demonstrated that
formalin induces a selective activation of
ERK1/2 in the right CeLC (Carrasquillo
and Gereau, 2007). To test whether
mGluR5 activation in the right amygdala
is necessary for this inflammation-induced
change, we evaluated formalin-induced
ERK1/2 activation following amygdalar in-
fusion of MPEP or vehicle. WT mice were
given right paw intraplantar injections of
formalin and 2 h later were administered
with eitherMPEP (0.01 nmol) or vehicle via
right intra-amygdala infusion. Comparing
the right amygdala between the two groups,
we founda significant decrease inERK1and
ERK2 activation 3 h after formalin in the
MPEP-treatedgroupcomparedwith theve-
hicle group (Fig. 5C,D), suggesting that
mGluR5 is necessary for formalin-induced
ERK1/2 activation in the amygdala.
Although mGluR5 inhibition in the
right amygdala was sufficient to reverse
formalin-induced mechanical hypersen-
sitivity, we also tested whether blocking
mGluR5 activation in the left amygdala
might have an effect on this nociceptive
response. WT mice were given right paw
intraplantar injections of formalin (2% in
saline) and treated 2 h later with either
MPEP (0.01 nmol) or vehicle via left
intra-amygdala infusion. In all animals
tested, withdrawal thresholds to mechan-
ical stimuli in both pawswere significantly
reduced at both 1 and 3 h after formalin







Figure 4. DHPG and ERK activation in the amygdala.A, Representative sections showing immunofluoresence (white) for phosphory-
latedERK1/2 in theamygdala [whitedotted-line: top,0.1nmolofDHPG injected30minbeforekill; bottom,vehicle (aCSF) injected30min
before kill]. B, Representative Western blot showing phosphorylated (Phospho) ERK1 and ERK2 bands (top) and total ERK1 and ERK2
(bottom) frommice injected in the right amygdala (Amy)with either vehicle (n8) or DHPG (0.1 nmol,n8) before being killed.C,D,
Quantification ofWestern blots showing increased activation of ERKbyDHPG comparedwith vehicle.C, Activated ERK1 is increased in the
right amygdala of DHPG-treated mice compared with the left amygdala of DHPG-injected mice and vehicle-injected right amygdala
samples.D,ActivatedERK2is increasedintherightamygdalaafterDHPGinjectioncomparedwithleftamygdalaofDHPG-injectedmiceand
vehicle-injected rightamygdala samples.E,F, Rightamygdalacoinfusionof0.1nmolofDHPGwith theMEK1/2 inhibitorU0126(1.5nmol,
n6) inducesreducedmechanicalhypersensitivitycomparedwithcoinfusionofDHPGplusU0124(inactivecontrolanalogofU0126,n
5) in both the left (E) and right (F ) paws.G, RepresentativeWestern blot showing phosphorylated ERK1 and ERK2 bands (top) and total
ERK1andERK2 (bottomblot) frommice injected in the right amygdalawithDHPGandU0124 (n5)orDHPGandU0126 (n6)before
being killed. H, Quantification of right amygdala tissue sample Western blot showing reduced ERK1 and ERK2 phosphorylation in mice
injectedwithU0126plusDHPGcomparedwithmice injectedwithU0124plusDHPG.Gray area inbrain illustration is representative ofWT
mGluR5 expression. Scale bars, 200m. Data are expressed as mean SEM. Graphs of Western data are normalized to control left
amygdala protein expression. Repeated-measures ANOVAwith Bonferroni post-test: *p 0.05, **p 0.01, ***p 0.001, compared
with specified sample (C,D) or othergroupat indicated timepoint (E,F ); #p0.05, ##p0.01, ###p0.001, comparedwithbaseline
for specified group; unpaired Student’s t test:p 0.05.
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contrast to our results of MPEP infusion into the right amygdala,
MPEP infusion into the left amygdala did not induce changes in
withdrawal thresholds compared with vehicle-treated mice. To-
gether, these results suggest that mGluR5 in the right CeA only is
necessary for the full mechanical behavioral response to in-
traplantar formalin.
Genetic disruption of mGluR5 blocks formalin-induced
mechanical hypersensitivity
The specific role for mGluR5 in formalin-induced mechanical
hypersensitivity was also verified by testing mGluR5KO mice and
WT littermates in the von Frey test. In accordance with our base-
line results above,withdrawal thresholds for
mGluR5KO mice were significantly greater
than those of WT littermates in the right
paw (Fig. 6B). Interestingly, intraplantar
formalin induced mechanical hypersensi-
tivity in both hindpaws of WT mice but
only in the injected (right) hindpaw of
mGluR5KOmice (Fig. 6A,B). Furthermore,
withdrawal thresholds of mGluR5KO mice
were significantly greater than those of WT
littermates for both paws 3 h after formalin
injection.
To confirm deletion of mGluR5 in
mGluR5KO mice, amygdala tissue was
probed formGluR5 expression usingWest-
ern blotting. Representative blots in Figure
6C clearly show an absence of mGluR5 sig-
nal in KO mice compared with WT litter-
mates. In addition, as ERK is preferentially
activated in the right amygdala ofWTmice
during inflammation (Carrasquillo andGe-
reau, 2007, 2008), WT amygdala samples
were probed to see whether mGluR5 pro-
tein expressionmight differ between the left
and right amygdalas. mGluR5 expression is
significantly higher in the right amygdala
relative to the left (Fig. 6C) (pairedStudent’s
t test p  0.021). We also tested to see
whether there might be a lateralization of
total ERK1/2 in the amygdala of WT and
mGluR5KO mice. Comparing right amyg-
dala ERK1 or ERK2 expression relative to
left amygdala expression, we found no sig-
nificant lateralization of either isoform for
either genotype and no differences between
genotypes (data not shown).
Targeted disruption of amygdalar
endocrine feedback does not
inhibit formalin-induced
mechanical hypersensitivity
An important question in understanding
the amygdala’s role in processing persistent
inflammatory pain is whether nociceptive
behavior is influenced by endocrine inputs
to the amygdala. A component of the phys-
iological response to formalin in mice is an
activation of the hypothalamic-pituitary-
adrenal (HPA) axis leading to an increase
in circulating glucocorticoids (e.g., corti-
costerone) (Vissers et al., 2003, 2004),
which can bind GRs in the amygdala to induce cellular changes.
With regard to the present study, corticosterone and the HPA
axis have been linked to mGluR5 and pain-related cellular and
behavioral changes (Greenwood-Van Meerveld et al., 2001;
Bradbury et al., 2003). As such, we wanted to know whether GR
disruption in the amygdala would influence long-lasting me-
chanical hypersensitivity induced by persistent inflammation. As
previously reported, lentiviral-mediated conditional CeA-
specific GR knock-out (GRCeAKO) mice have GRs disrupted in
60–75% of neurons compared with control mice (Kolber et al.,
2008). Here, mechanical thresholds were evaluated at baseline
and 3 h after right hindpaw formalin injection in GRCeAKO and
Figure 5. mGluR5 activation is necessary for formalin-induced mechanical hypersensitivity and ERK1/2 activation. A–F, Mice
are injected in the right pawwith formalin at time 0min.A,B, Intra-right amygdalaMPEP (0.01 nmol, n 6 at 120min) reverses
mechanical hypersensitivity in the noninjected paw (A) and reduces hypersensitivity in the injected paw (B) compared with
predrug measurements (at 60 min) and baseline values. In addition, MPEP-treated mice exhibit increased withdrawal thresholds
comparedwith thoseof intra-right amygdala vehicle-treatedmice (n6).C,D, Intra-right amygdalaMPEP (0.01nmol at 120min
after intraplantar formalin) reverses formalin-induced ERK1/2 activation in the right amygdala (Amy). C, RepresentativeWestern
blot showing phosphorylated ERK1 and ERK2 bands (top) and total ERK1 and ERK2 (bottom) from mice injected in the right
amygdala withMPEP (n 8) or vehicle (n 8) 60min before kill (180min after intraplantar formalin).D, Quantification of right
amygdala tissue sample Western blots showing reduced ERK1 and ERK2 phosphorylation in mice injected with MPEP compared
with samples from mice injected with vehicle. E, F, Intra-left amygdala MPEP (0.01 nmol, n 5 at 120 min) does not reverse
mechanical hypersensitivity in either the noninjected (E) or injected paw (F ). Furthermore, left-amygdala MPEP-treated mice do
not exhibit different withdrawal thresholds compared with those of intra-left amygdala vehicle-treatedmice (n 6) at any time
point after formalin injection. Gray areas in brain illustrations are representative of WTmGluR5 expression. Data are expressed as
mean SEM. Graphs of Western data are normalized to control left amygdala protein expression. Repeated-measures ANOVA
with Bonferroni post-test: ***p 0.001, comparedwith vehicle-treated group at specified time point; #p 0.05, ###p 0.001,
compared with baseline for specified group; unpaired Student’s t test:p 0.01.
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control mice. Formalin injection resulted
in a significant reduction in mechanical
sensitivity in both paws of GRCeAKO and
control mice. There were no significant
differences between genotypes at any time
point (Fig. 6D,E). These data suggest that
GR expression in the CeA (and therefore
endocrine feedback onto CeA neurons) is
not necessary for formalin-induced me-
chanical hypersensitivity.
Disruption of mGluR5 in the right
amygdala reduces inflammatory pain
Both pharmacological inhibition of mGluR5
and global disruption of mGluR5 expres-
sion reduce inflammatory pain. Further-
more, mGluR5 expression is expressed at
higher levels in the right amygdala relative
to the left amygdala. These data are con-
sistent with the hypothesis that mGluR5
activation in the right amygdala is critical
to the behavioral response to formalin-
induced inflammation. To further test
this hypothesis, a conditional knock-out
approach was used to disrupt mGluR5 se-
lectively in the right amygdala. Mice ho-
mozygous for the floxed-mGluR5 allele or
WT littermateswere injected into the right
amygdala with recombinant lentivirus ex-
pressingCre recombinase (LV-Cre). Floxed
mGluR5 mice injected with LV-Cre
(mGluR5CeAKO) exhibited a significant de-
crease in mGluR5 expression in the right
amygdala compared with the right amyg-
dala of LV-Cre-injectedWT (control) mice
(unpaired Student’s t test p  0.01) (Fig.
7A). Similar toWTmice above, control LV-
Cre-injected mice exhibited significantly
higher mGluR5 expression in the right
amygdala relative to the left amygdala
(paired Student’s t test p 0.049) (Fig. 7A).
Toaddresswhether theobserveddecrease in
mGluR5 expression (in mGluR5CeAKO
mice)was specific or reflected an overall de-
crease in protein expression in amygdala tissue, we evaluated GR
expression. No differences in amygdala GR expression were found
between mGluR5CeAKO and control mice, and no significant later-
alization of GR was found in either genotype (Fig. 7B).
To examine the behavioral effects of right amygdala mGluR5
disruption, we measured spontaneous formalin-induced behav-
ior in mGluR5CeAKO and control mice. In addition to changes to
mechanical sensitivity, intraplantar formalin injection induces a
stereotyped biphasic, spontaneous behavioral response in the
first 60 min following injection (Tjolsen et al., 1992). Conven-
tional global mGluR5KO mice have a decreased second phase of
this response (Montana et al., 2009). In contrast, we found no
significant differences between mGluR5CeAKO and control mice
in either the first phase (control: n  4, 267.3  32.73 s;
mGluR5CeAKO: n 3, 254.7 34.67; p 0.81) or second phase
(control: n 4, 709.8 39.89 s; mGluR5CeAKO: n 3, 685.3
44.46; p 0.48) of spontaneous behavior testing (Fig. 7C).
Next, we examined mechanical sensitivity in mGluR5CeAKO
mice and control mice under baseline conditions and following
intraplantar formalin injection. In the von Frey test at baseline,
mGluR5CeAKO mice exhibited no significant differences in me-
chanical withdrawal thresholds compared with those of control
mice (Fig. 7D,E). However, 3 h after formalin injection,
mGluR5CeAKO mice exhibited increased mechanical withdrawal
thresholds in the von Frey Test compared with thresholds of
control mice (Fig. 7D,E). When compared with baseline values,
injection of formalin induced significant mechanical hypersensi-
tivity in both hindpaws of control LV-Cre mice (Fig. 7D,E) but
only induced significant hypersensitivity in the injected (right)
hindpaws of mGluR5CeAKO mice (Fig. 7E). Overall, these data
suggest that mGluR5 expression in the right amygdala is neces-
sary for normal formalin-induced hypersensitivity.
Discussion
The findings of this study provide a mechanistic framework for
the emerging role of the amygdala in themodulation of persistent
pain due to peripheral inflammation. We demonstrate that
mGluR5 activation in the amygdala is sufficient to induce me-
Figure 6. Genetic disruption of mGluR5 but not GR expression prevents normal formalin-inducedmechanical hypersensitivity.
A, B, In response to right paw formalin-injection, conventional mGluR5 KO mice (n 9) show no hypersensitivity in the left paw
compared with baseline and reduced hypersensitivity in both paws compared with WT mice (n 7) (A). mGluR5 KO mice show
increased basal withdrawal responses in the right paw compared with wild-type mice (B). C, Representative Western blots for
mGluR5 (top) and-tubulin (bottom) in mGluR5 KO mice andWTmice. Quantification of Western blot shows no mGluR5 expres-
sion inmGluR5 KOmice (n7) and significantly highermGluR5expression in right amygdala (Amy) relative to left amygdala inWT
mice (n 7). D, E, Deletion of GR bilaterally (GR CeAKO, n 9) does not induce any behavioral changes under basal conditions or
following right paw formalin injection in the noninjected (left) (D) or injected (E) (right) paw compared with control vector-
injectedmice (control, n 9). White area in top brain illustration is representative of areas wheremGluR5 is disrupted; blue area
in bottombrain illustration is representative of areas ofWTGR expression;white area in bottombrain illustration is representative
of disruption of GRbilaterally in the CeA. Data are expressed asmean SEM. Graphs ofWestern data are normalized to control left
amygdala protein expression. Repeated measures ANOVA with Bonferroni post-test: **p 0.01, ***p 0.001, compared with
control genotype at specified timepoint; #p0.05, ##p0.01, ###p0.001, comparedwith samegenotype at baseline; paired
Student’s t test: p 0.05.
8210 • J. Neurosci., June 16, 2010 • 30(24):8203–8213 Kolber et al. •mGluR5 in the CeA Modulates Pain-Like Behavior
chanical hypersensitivity in the absence of injury and that
mGluR5 activation is necessary for the development of mechan-
ical hypersensitivity in response to inflammation. Furthermore,
we provide evidence for hemispheric lateralization of amygdala
function and mGluR5 expression. In addition, we find that
mGluR5-related effects are linked to ERK1/2 activation in the
amygdala. These results support the hypothesis that mGluR5 sig-
naling via ERK phosphorylation in the right amygdala plays an
important role in the neuromodulation of persistent pain.
Interestingly, we demonstrate that activation of group I
mGluRs in the right amygdala is sufficient to induce bilateral
mechanical hypersensitivity. This result is of particular relevance
to pain conditions that exist in humans that do not have a
known underlying etiology (e.g., fibromyalgia). As both
mGluR1 and mGluR5 are expressed in the amygdala, we
sought to clarify the necessity for mGluR5 in DHPG-induced
hypersensitivity. Disruption of mGluR5 (pharmacologically
or genetically) significantly reduces the effects of DHPG.
These data suggest that mGluR5 activation alone in the right
amygdala is sufficient to induce mechanical hypersensitivity
but do not preclude a role for mGluR1 signaling in the amyg-
dala during nociceptive processing.
The amygdala is involved in both ascending and descending
components of nociceptive pathways (Bernard et al., 1989). No-
ciceptive input to the CeA via the spino-parabrachio-amygdaloid
pathway or the BLAmay provide a source of glutamatergic inputs
to the CeLC (Neugebauer et al., 2004). As such, the amygdala is
uniquely situated to modulate behavior during prolonged pain
conditions, such as those seen after in-
traplantar formalin injection. mGluR5 is
necessary for the full expression of central
sensitization and the exhibition of second
phase nociceptive behaviors in the spon-
taneous formalin test (Bhave et al., 2001;
Karim et al., 2001a; Adwanikar et al.,
2004; Montana et al., 2009). Intraplantar
formalin injection also induces persistent
hypersensitivity to mechanical and ther-
mal stimuli (Fu et al., 2001; Carrasquillo
and Gereau, 2007). Interestingly, global
mGluR5 disruption reduces but does not
eliminate mechanical hypersensitivity in
the formalin-injected paw. The observed
reduction is only partial due to ongoing
local inflammation at the site of formalin
injection and resultant peripheral sensiti-
zation. However, a caveat of this finding is
the demonstration that mGluR5KO mice
exhibit a reduced acute behavioral re-
sponse to formalin injection in the paw
(Montana et al., 2009) and hyporespon-
siveness to mechanical stimulation under
baseline conditions. The observation that
mGluR5 antagonists do not alter base-
line mechanical sensitivity in naive mice
(Walker et al., 2001) suggests that our ob-
served baseline differences in mGluR5KO
mice are likely a result of compensatory
changes associated with global deletion of
mGluR5.
To circumvent these issues, we devel-
oped amousewith unilateral CeA-specific
deletion of mGluR5 (mGluR5CeAKO) by
injecting the CeA of mice carrying floxed mGluR5 alleles (Xu et
al., 2009)with aCre recombinase-expressing lentivirus (Kolber et
al., 2008). ThesemGluR5CeAKOmice had40–50% reduction in
mGluR5 expression in the right amygdala comparedwith control
mice. This value may be an underestimate of disruption of
mGluR5 in these mice due to the possible expression of mGluR5
in glial cells (Ferraguti et al., 2001). The observed reduction in
mGluR5 protein expression does not reflect a nonspecific de-
crease in protein expression, as mGluR5CeAKO mice express
equivalent amounts of GR protein compared with controls.
mGluR5CeAKO mice show significant reduction in formalin-
induced mechanical hypersensitivity, but no changes in baseline
sensitivity or spontaneous responses to formalin injection. These
data are consistent with previous work showing that the amyg-
dala is not involved in baseline nociception (Manning and
Mayer, 1995b; Carrasquillo and Gereau, 2007) or acute formalin
responses (Manning andMayer, 1995a; Carrasquillo andGereau,
2007).
To further test whether mGluR5 in the amygdala is neces-
sary for prolonged mechanical hypersensitivity, we used a
pharmacological approach in WT mice to block mGluR5 in
the right amygdala after formalin paw injection. We found
that formalin-induced mechanical hypersensitivity was re-
duced after right CeA MPEP infusion in a manner similar to
that seen with global mGluR5KO mice, consistent with the find-
ing that group I mGluR antagonists in the amygdala can inhibit
pain-like behaviors (Han and Neugebauer, 2005). In addition,




Figure 7. Conditional deletion of mGluR5 in the right amygdala prevents formalin-induced mechanical hypersensitivity. A,
Representative Western blot for mGluR5 (top) and -tubulin (bottom) in mGluR5 CeAKO and WT LV-Cre (control) mice. Graph of
mGluR5/-tubulin shows reduced mGluR5 expression in the right amygdala of mGluR5 CeAKO mice (n 6) [compared with the
right amygdala of control mice (n 6)]. The graph also shows significantly higher mGluR5 expression in the right amygdala
relative to the left amygdala in control mice. B, Representative Western blot for glucocorticoid receptor (top) and -tubulin
(bottom) inmGluR5 CeAKOmice and control mice. Graph shows no differences betweenmGluR5 CeAKO or control mice in GR expres-
sion in the right or left amygdala and no lateralization of GR expression in either genotype. C, mGluR5 CeAKOmice show equivalent
spontaneous behavior (lifting, licking, scratching of injectedpaw) following formalin injection comparedwith that of controlmice.
D, E, Disruption of mGluR5 in the right CeA leads to a complete block of hypersensitivity in the noninjected (left) paw (D) and
reduced hypersensitivity in the injected (right) paw (E) after formalin injection and reduced hypersensitivity in both paws com-
pared with control mice. Gray area in brain illustration is representative of WTmGluR5 expression; white area in brain illustration
is representativeofmGluR5disruption in the right CeA.Data are expressedasmeanSEM.GraphsofWesterndata arenormalized
to control left amygdala protein expression. Repeated-measures ANOVAwith Bonferroni post-test: ***p 0.001 comparedwith
control genotype at specified time point; ##p 0.01, ###p 0.001 compared with same genotype at baseline; paired Student’s
t test: p 0.05; unpaired Student’s t test: p 0.01.
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fore intra-amygdala drug infusions, suggesting that mGluR5 ac-
tivation in the amygdala may be involved in the maintenance of
persistent pain-like behavior.
Our data indicate that some aspects ofmGluR5modulation of
pain-like behavior are lateralized to the right amygdala.We find a
higher level of mGluR5 expression in the right amygdala com-
pared with expression in the left amygdala under normal condi-
tions. These findings are not without precedent, as hemispheric
lateralization of amygdala function has been reported in both
humans (Coghill et al., 2001; Cahill et al., 2004; Lu et al., 2004;
Alkire et al., 2008) and rodents (Lalumiere and McGaugh, 2005;
Ji and Neugebauer, 2009). Previously, we established that during
formalin-induced inflammation, there is a selective activation of
ERK1/2 in the right CeLC that can be blocked with the MEK1/2
inhibitor U0126 (Carrasquillo and Gereau, 2008). In addition,
recent data show hemispheric lateralization of amygdala sensiti-
zation in arthritis (Ji and Neugebauer, 2009). Interestingly, in
that study, neurons of the right CeLC showed whole-body recep-
tive fields, while left CeLC neurons showed more restricted con-
tralateral receptive fields. Our observation of baseline differences
in mGluR5 protein reflects either more mGluR5 protein per cell
in the right amygdala or expression of mGluR5 in an additional
population of cells in the right amygdala relative to the left. Al-
though future studies will be needed to clarify this issue, the data
showing larger receptive fields of right amygdala neurons (Ji and
Neugebauer, 2009), our data showing that DHPG infusion in the
right amygdala induced bilateral tactile hypersensitivity whereas
DHPG infusion in the left amygdala induced mechanical hyper-
sensitivity in the right (contralateral) paw only, and our data
showing that MPEP could reverse formalin-induced mechanical
hypersensitivity when infused into the right but not left amygdala
suggest that theremay be a unique population of cells in the right
amygdala that have bilateral connections within the CNS.
Three lines of evidence suggest that amygdalar mGluR5 is
functionally coupled to ERK and that this signaling pathway is
involved in endogenous pain modulation. First, we show that
activation of mGluR5 in the right amygdala induces activation of
ERK1/2. Second, we demonstrate that the behavioral effects of
DHPG can be reduced following coinfusion with theMEK inhib-
itor U0126. Finally, we show that mGluR5 inhibition in the right
amygdala blocks formalin-induced ERK1/2 activation in the
right amygdala. In the CeA, ERK1/2 is both necessary and
sufficient for formalin-induced mechanical hypersensitivity
(Carrasquillo and Gereau, 2007, 2008). In the spinal cord dorsal
horn, mGluR5-induced ERK activation modulates both sponta-
neous behavioral responses to formalin and neuronal excitability
via increasing ion channel phosphorylation (Karim et al., 2001a;
Hu and Gereau, 2003; Hu et al., 2007). Additional studies will be
necessary to determine whether similar mechanisms are respon-
sible for DHPG-induced modulation of behavior at the level of
the amygdala. Interestingly, coinfusion of DHPG with the MEK
inhibitor U0126 caused only a partial reversal of DHPG-induced
mechanical hypersensitivity. These data suggest signaling path-
ways unrelated to ERK may be involved in mGluR5-related be-
havioral changes.
During stressful events, including formalin injection (Vissers
et al., 2003, 2004), the HPA axis is activated causing the release of
corticosterone, which binds to GR. Corticosterone-induced activa-
tion of amygdalar GR can increase colorectal distension-induced,
pain-related responses in rats (Greenwood-Van Meerveld et al.,
2001). Furthermore, systemic MPEP induces HPA axis activation,
suggesting the possible presence of a functional coupling ofmGluR5
and the endocrine stress response (Bradbury et al., 2003). To test the
hypothesis that amygdalar GR is playing an underlying role in
formalin-inducedmechanical hypersensitivity,we evaluated this be-
havior after bilateral conditional knock-out of GR in the CeA. We
found no differences in formalin-induced mechanical hypersensi-
tivity in theseGRCeAKOmice, although it is possible that the remain-
ing population ofGR-positive neuronswas able tomaintain normal
feedback during inflammatory pain. However, this is unlikely be-
cause we described previously a reduction in conditioned fear in
GRCeAKO mice with only 65% CeA GR disruption (Kolber et al.,
2008).
Overall, we show that CeA mGluR5 activation is both neces-
sary for the development of inflammatory pain-like behavior and
sufficient to inducemechanical hypersensitivity in the absence of
injury. Furthermore, we demonstrate that the behavioral effects
of mGluR5 activation are mediated via ERK activation in the
CeA. In addition, we find hemispheric differences in mGluR5
expression and mGluR5 activation-induced behavior. Our re-
sults have important implications for understanding chronic
pain in human patients. Specifically, we identify mGluR5 as an
important cellular component of amygdala pain modulation,
whichmay provide amolecular connection to the known efficacy
of cognitive and behavioral approaches to pain treatment in hu-
man patients; our results demonstrate a specific anatomical loca-
tion that may underlie some of the many preclinical studies
showing the potential efficacy of mGluR5 antagonists in the
treatment of pain.
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